How a Stomach Cancer Tumor Board Decides Between Surgery First and Chemotherapy First

The phone call comes on a quiet weekday afternoon. The nurse is kind and unhurried, and she says a sentence that sounds like a code: “Your case goes to the board later this week.” Nobody said “board” in the endoscopy suite. Nobody mentioned a committee. Yet somewhere in a hospital conference room, a dozen people who have never met you are about to spend a few concentrated minutes deciding whether your stomach cancer should meet a scalpel first or a drip first.

That room is the stomach cancer tumor board, and the question it wrestles with is one of the most consequential in cancer care. Operate now and you remove the tumor you can see. Treat first with chemotherapy and you may shrink it, test how it behaves, and hunt for cancer the scans could not catch. Each path has a logic, and each has a cost.

This explainer walks through what actually happens at that table, what information the board needs, who tends to be sent one way or the other, and what the following weeks usually look like.

What is a tumor board, and who sits around the table?

A tumor board is a regular meeting at which specialists from different fields review individual cancer cases and agree on a recommended treatment plan. The National Cancer Institute defines it in almost exactly those words, and the idea is simple: no single doctor sees the whole picture, so the picture is assembled in one room.

For stomach cancer, the usual cast includes a surgical oncologist or upper gastrointestinal surgeon, a medical oncologist who prescribes chemotherapy and targeted drugs, a radiation oncologist, a radiologist who reads the CT and PET scans, a pathologist who has examined the biopsy under a microscope, a gastroenterologist who performed the endoscopy, and a clinical nurse specialist who knows the patient as a person rather than a slide. Many boards also seat a dietitian, a palliative care physician and a clinical trials coordinator. In the UK the same forum is called the multidisciplinary team meeting, or MDT, and NHS guidance describes stomach cancer care as being planned by exactly this kind of team.

The patient is almost never in the room. That surprises people, and it can feel like being talked about behind a door. The practical reason is volume: a single board may review twenty or more cases in an hour, each one presented in a few tightly structured minutes. The outcome is not a verdict handed down but a recommendation that your own oncologist or surgeon then brings back to you, explains, and adjusts for your preferences.

Think of it less as a jury and more as a second, third and fourth opinion delivered simultaneously, with the scans on the screen and the pathologist able to correct the surgeon in real time.

How a stomach cancer tumor board actually works, minute by minute

The meeting follows a rhythm that is remarkably consistent across hospitals. A coordinator calls the case. The presenting doctor, often the gastroenterologist or surgeon who first saw you, gives a short summary: age, general health, how the cancer was found, what the endoscopy showed, and where in the stomach the tumor sits. Location matters more than most patients realize, because a tumor at the top of the stomach near the esophagus is handled differently from one near the exit into the small intestine.

The radiologist then puts the CT images on the main screen and walks the room through them. How thick is the stomach wall where the tumor is? Are nearby lymph nodes enlarged? Is there anything in the liver, the lungs, the lining of the abdomen? If a PET scan was done, the radiologist describes any bright spots that take up the tracer.

The pathologist speaks next. The biopsy confirms adenocarcinoma, the common type arising from gland cells in the stomach lining, or occasionally something rarer. The pathologist may report whether the tumor is of the intestinal or diffuse type, and whether biomarker results are back: HER2, a growth protein that some stomach cancers overproduce; PD-L1, a marker relevant to immunotherapy; and mismatch repair or microsatellite status, which flags a DNA-repair defect.

Only then does the discussion begin. The surgeon says what an operation would involve and whether it is technically feasible. The medical oncologist says what drug treatment could offer before or instead of surgery. The nurse specialist raises anything the patient has said about priorities, fears or home circumstances. Within a few minutes a consensus forms, is recorded, and the next case is called.

What the board needs before it can decide: staging explained

Staging is the process of working out how far a cancer has grown and whether it has spread, and it is the single piece of information that most shapes the surgery-first versus chemotherapy-first decision. Doctors describe stomach cancer stage using three letters. T is how deeply the tumor has grown into or through the stomach wall. N is whether, and how many, nearby lymph nodes contain cancer. M is whether there are metastases, meaning deposits in distant organs.

The tests that supply those letters are familiar from any stomach cancer diagnosis and are described plainly by the NHS and Mayo Clinic: an upper endoscopy with biopsy, a CT scan of the chest, abdomen and pelvis, and often an endoscopic ultrasound, in which a tiny ultrasound probe on the tip of the endoscope measures how deep the tumor reaches and looks at the nearest lymph nodes. A PET-CT scan may be added to search for spread the CT could miss.

One test deserves special mention because it changes plans more often than any other: staging laparoscopy. A surgeon makes a few small incisions, inserts a camera, and inspects the surface of the liver and the lining of the abdominal cavity, sometimes washing the cavity with fluid and sending it for analysis. Tiny seedlings of cancer on the peritoneum, the membrane lining the abdomen, are notoriously invisible on CT. Finding them moves a patient from an operable plan to a drug-led plan before anyone has undergone a major operation.

If any of these results are missing, the board usually does the sensible thing and defers. A decision made on incomplete staging is a guess, and nobody at that table wants to guess.

Why chemotherapy before stomach cancer surgery became the default for locally advanced disease

For much of the twentieth century, the answer to a stomach cancer that looked operable was straightforward: operate. Cancer that came back later was treated as bad luck. The problem was that it came back often, usually in the liver or the peritoneum, which told surgeons that microscopic disease had already escaped the stomach before the first incision.

The turning point was a large randomized trial, usually called the MAGIC trial, published in the New England Journal of Medicine and indexed on PubMed. It compared surgery alone with chemotherapy given both before and after surgery, a pattern known as perioperative chemotherapy, in patients with operable stomach and lower esophageal adenocarcinoma. Patients who received the perioperative approach lived longer on average, and their tumors were smaller at the time of operation. Later trials refined the drug combinations, but the principle held: treating the whole body before removing the primary tumor addresses the invisible cells that surgery alone cannot reach.

The mechanism is worth understanding. Chemotherapy drugs circulate through the bloodstream and damage rapidly dividing cells wherever they are. Given before surgery, they reach micrometastases while blood supply to the tumor region is intact and the patient is at full strength. They also act as a biological test: a tumor that shrinks on scans is one that is sensitive to that drug class, information the oncologist can use when planning post-operative treatment.

Both the NHS treatment page and the National Cancer Institute’s patient treatment summary now describe chemotherapy before and after surgery as a standard option for stomach cancers that have grown through the wall or involved lymph nodes but have not spread further. That is the category of patient most likely to hear the board say “chemotherapy first.”

Who is usually sent to surgery first, and who is usually asked to wait

The board sorts patients into broad groups, and understanding which group you fall into explains most of what you will hear afterward.

Surgery or endoscopic removal first is typically favored when the cancer is very early, confined to the innermost lining of the stomach with no suspicious lymph nodes. The National Cancer Institute’s treatment summary lists endoscopic mucosal resection, in which the tumor is peeled away through the endoscope without any external incision, as an option for the smallest, shallowest tumors. For early tumors slightly deeper than that, a gastrectomy without preceding chemotherapy is common, because the chance of hidden spread is low and the extra months of drug treatment would carry side effects with little expected benefit.

Chemotherapy first is the usual recommendation for the middle group: tumors that have grown into the muscle layer or beyond, or scans suggesting lymph node involvement, but no evidence of distant spread. This is the population studied in the MAGIC trial and its successors.

Surgery first despite a larger tumor still happens in specific situations. A tumor that is bleeding persistently, or one blocking the stomach’s exit so the patient cannot eat, may need an operation urgently. Some patients are judged too frail for chemotherapy but fit enough for a limited operation. Others simply decline drug treatment after an honest conversation.

Drug treatment first and possibly only applies when staging shows spread to the liver, lungs, distant lymph nodes or peritoneum. Here the board is not choosing the order of two treatments; it is recommending that systemic therapy lead, with surgery reserved for relieving symptoms if they arise.

Fitness threads through every category. A measure called performance status, a simple scale of how much daily activity someone can manage, is read aloud for nearly every case.

Surgery first vs chemotherapy first: a side-by-side summary

Patients often ask for the decision laid out plainly. The table below summarizes the typical reasoning a board applies, drawn from the treatment approaches described by the NHS, Mayo Clinic and the National Cancer Institute. It is a map of common patterns, not a rule for any individual.

Factor the board weighs	Leans toward surgery or endoscopic removal first	Leans toward chemotherapy first
Depth of tumor (T stage)	Confined to the inner lining or just beneath it	Into the muscle layer or through the stomach wall
Lymph nodes on imaging	None appear involved	One or more look enlarged or abnormal
Distant spread (M stage)	None found, including at staging laparoscopy	None found, but risk of hidden spread is judged meaningful
Urgent problems	Uncontrolled bleeding or a blocked stomach outlet	Eating and blood counts are stable
General fitness	Fit for an operation but unlikely to tolerate chemotherapy	Fit enough for several weeks of drug treatment and then surgery
Tumor location	Mid or lower stomach, early stage	Junction with the esophagus, where chemoradiation may also be considered
Patient preference	Wishes to avoid drug treatment after informed discussion	Accepts the longer pathway for the potential benefit

Two observations about this table matter more than any single row. First, most rows interact: a very early tumor in a frail patient points one way, a locally advanced tumor in a fit patient points the other, and mixed pictures are where the board earns its keep. Second, “chemotherapy first” nearly always implies “and surgery after,” because the aim in that group is still to remove the tumor completely. The sequencing changes; the destination does not.

When neither comes first: how the board approaches stage 4 stomach cancer

Stage 4 means the cancer has spread beyond the stomach and nearby lymph nodes to distant sites. When staging confirms this, the question in the title largely dissolves. The board is no longer debating which of two treatments leads; it is recommending a plan in which systemic treatment, meaning drugs that travel through the whole body, is the backbone.

Those drugs include conventional chemotherapy and, depending on the biomarkers the pathologist reported, targeted agents and immunotherapy. If the tumor overproduces HER2, an antibody that blocks that protein may be added to chemotherapy; the National Cancer Institute’s treatment summary describes this approach. If PD-L1 expression or a mismatch repair defect is present, immune checkpoint inhibitors, drugs that release the brakes on the body’s own immune cells, may be discussed. Which combination is appropriate, and in what sequence, is a decision for the prescribing oncologist after reviewing the full report.

Surgery does not vanish from the conversation. A board may recommend an operation, a stent or a feeding tube to relieve a blocked stomach, or an endoscopic procedure to control bleeding, even when removing all the cancer is not the goal. These are described in neutral terms as palliative procedures, which simply means they are done to relieve symptoms and protect quality of life.

Patients frequently ask how long someone with stage 4 stomach cancer typically lives. Honest doctors resist quoting a single number, and so does this article. Published averages mix together people of very different ages, fitness, tumor biology and treatment access, and newer biomarker-guided therapies have shifted the picture for some subgroups. Your oncologist can discuss what the evidence suggests for your specific situation, and asking that question directly is entirely reasonable.

What happens in the days and weeks after the tumor board meets

The meeting ends, and a letter or electronic note records the recommendation. What follows depends on which path was chosen, but the shape is predictable.

If the recommendation is chemotherapy first, your medical oncologist meets you to explain the proposed regimen, its common side effects and the monitoring involved. Blood tests check kidney function and blood counts. Many patients need a small device placed under the skin of the chest, called a port, to make repeated intravenous treatment easier. In the FLOT4 trial, the most influential recent study of this approach, the pre-operative phase lasted roughly two months before a planned gap and then surgery, and most modern programs follow a broadly similar rhythm. A repeat CT scan near the end of that phase tells the team whether the tumor has shrunk, stayed the same or grown, and the case usually returns to the board for a second look before the operation is scheduled.

If the recommendation is surgery first, the pathway moves to pre-operative assessment: heart and lung checks, an anesthetic review, a dietitian visit and sometimes a short program of exercise and nutrition to build reserve before a major operation. After surgery, the removed stomach and lymph nodes go to the pathologist, and the case returns to the board a third time. The final pathology report, which shows exactly how deep the tumor went and how many nodes were involved, determines whether chemotherapy after surgery is recommended.

In every scenario the nurse specialist remains the fixed point. If something in the plan is unclear, that is the person to call, and the plan can be revisited at any stage.

What stomach cancer surgery actually involves

Gastrectomy means surgical removal of part or all of the stomach, and understanding its two main forms helps make sense of the board’s discussion. A subtotal gastrectomy removes the lower portion of the stomach, leaving the upper part attached to the small intestine. A total gastrectomy removes the entire stomach and joins the esophagus directly to the small intestine. The choice depends mostly on where the tumor sits and how much healthy margin the surgeon needs around it.

In both operations, the surgeon also removes the lymph nodes that drain the stomach, a step called lymphadenectomy. This is not optional housekeeping. The nodes are where stomach cancer spreads first, and examining them under the microscope gives the most accurate stage and guides every decision afterward. The NHS and Mayo Clinic both describe node removal as a standard part of the operation.

Surgery may be performed through a single long incision or using keyhole techniques with a camera and long instruments, sometimes robot-assisted. The board may comment on which approach is suitable, but the operating surgeon makes the final technical call.

Risks are real and are discussed in plain terms during consent: bleeding, infection, a leak at the join between esophagus or stomach and intestine, pneumonia, blood clots, and the longer-term consequences of living with a smaller or absent stomach. Those longer-term effects include needing smaller, more frequent meals, a tendency for food to pass too quickly into the intestine, and the need for vitamin B12 supplementation after total gastrectomy, because the stomach makes the protein that allows B12 to be absorbed.

None of this is a reason to fear the operation. It is the reason the board insists on knowing a patient’s fitness before recommending it.

What chemotherapy before surgery is designed to do, and what it cannot tell you in advance

Pre-operative chemotherapy has three jobs. The first is to treat cancer cells that may have already left the stomach, the microscopic spread discussed earlier. The second is to shrink the primary tumor, which can make an operation technically easier and, in some cases, allow a less extensive one. The third is diagnostic: it reveals whether this particular cancer responds to this class of drugs, which informs what happens after surgery.

The drugs used are usually combinations of agents from a few long-established classes, including platinum compounds, fluoropyrimidines and taxanes, each of which interferes with cell division in a different way. Modern regimens are typically given in cycles, meaning a period of treatment followed by a rest to let healthy cells recover. Common side effects, listed by the NHS and Mayo Clinic, include fatigue, nausea, mouth soreness, lowered blood counts with increased infection risk, numbness or tingling in the hands and feet, and hair thinning. Your oncologist will describe the specific profile of the regimen proposed for you.

Here is what pre-operative chemotherapy cannot do, and it is important to hear it plainly. It cannot guarantee that the tumor will shrink. A proportion of tumors do not respond, and for those patients the board may decide to proceed to surgery earlier or to change the drug plan. It cannot promise that the operation will then be simpler. And a good response on a scan does not guarantee that every cancer cell is gone.

Patients sometimes ask whether chemotherapy first means a delay that lets the cancer grow. The trials that established this approach compared it directly with immediate surgery, and the group that waited and received drugs first did better on average. The treatment during the wait is the point.

Eating, weight and strength: why the dietitian has a voice at the board

Stomach cancer is unusual among cancers in how directly it interferes with eating. The tumor may cause early fullness, pain after meals or a physical blockage, and many people have already lost weight by the time of diagnosis. That matters to the board for a practical reason: a patient who is malnourished tolerates both chemotherapy and surgery less well. Many teams therefore want a dietitian’s assessment before the sequence is finalized.

What should people with stomach cancer eat? The honest answer from mainstream sources such as the NHS and the National Cancer Institute is that there is no special anti-cancer diet, and no food has been shown to shrink a stomach tumor. The goal is protein and energy sufficient to maintain weight and muscle. In practice that often means small, frequent meals rather than three large ones, softer textures if swallowing or passage is difficult, and prescribed nutritional supplement drinks when ordinary food is not enough. If the stomach outlet is blocked, the board may recommend a stent, a small mesh tube that holds the passage open, or a feeding tube placed into the small intestine so nutrition continues while chemotherapy starts.

After gastrectomy the rules change again. Without a stomach reservoir, food enters the intestine quickly. Dietitians typically advise eating slowly, chewing well, separating drinks from meals, and limiting very sugary foods that can trigger dumping syndrome, the cramping, sweating and dizziness that occur when sugar rushes into the small intestine. Vitamin B12, iron and sometimes calcium and vitamin D need monitoring long term.

None of this is self-prescribed. The dietitian builds the plan with you, revisits it at each stage, and reports back to the team if weight is falling.

Does every cancer patient have a tumor board, and is a multidisciplinary team for stomach cancer always a good thing?

Not every cancer patient everywhere is discussed at a tumor board, but in many health systems it is now the expected standard for a new stomach cancer diagnosis. In the UK, the NHS describes treatment for stomach cancer as planned by a multidisciplinary team of specialists, and most cancer centers in the United States run disease-specific boards, including gastrointestinal boards where stomach, esophageal, pancreatic and bowel cancers are reviewed. Smaller hospitals may present cases to a regional board by video link, sometimes called an e-tumor board.

Is it a good thing before surgery? The evidence for tumor boards is observational rather than from randomized trials, because it would be difficult and arguably unethical to randomize patients to “no team discussion.” Studies summarized in the medical literature on PubMed consistently report that multidisciplinary review changes the diagnosis, stage or treatment plan in a meaningful minority of cases, most often by correcting staging or adding a treatment option that the referring doctor had not considered. Whether that translates into longer survival is harder to prove, and honest reviewers say so.

What the board reliably delivers is consistency. A surgeon enthusiastic about operating is balanced by an oncologist who knows the trial data; a pathologist can flag a biomarker result that opens the door to a targeted drug; a nurse can say that the patient lives alone and would struggle with a long chemotherapy pathway. Those checks happen in minutes rather than across weeks of separate appointments.

The limitation is equally real. A board can only judge the information in front of it. If the staging is incomplete or the patient’s own priorities were never recorded, the recommendation will be technically sound and personally wrong. That is why what happens after the meeting, in the room with you, matters as much as the meeting itself.

What people often get wrong about stomach cancer tumor boards

“Chemotherapy first means they think it’s too late to operate.” Usually the opposite. For locally advanced but operable cancer, chemotherapy before surgery is the recommended pathway precisely because the team intends to operate and wants to give that operation the best chance. The decision reflects stage, not despair.

“Surgery first means my cancer is worse, because they’re rushing.” Surgery first is most often chosen for the earliest tumors, where the chance of hidden spread is small enough that chemotherapy’s side effects are not worth it. Urgent surgery for bleeding or blockage is a different and less common situation, and your team will tell you which applies.

“The board decides and I have no say.” The board recommends. You decide, with your doctors, after hearing the reasoning, the alternatives and the risks. Declining a recommended treatment, asking for a second opinion, or asking the board to reconsider in light of something they did not know are all legitimate.

“A good CT scan means I don’t need the camera test.” Staging laparoscopy exists because CT misses small peritoneal deposits. Recommending it is thoroughness, not doubt about the radiologist.

“If the tumor shrinks on chemotherapy, maybe I can skip the operation.” For stomach adenocarcinoma, scans cannot confirm that every cell is gone, and current guideline-level practice still recommends removing the tumor and nodes after a response. Research into organ-preserving approaches is ongoing, but it is not standard care.

“Diet or supplements can replace treatment.” No food or supplement has been shown to treat stomach cancer. Nutrition supports treatment; it does not substitute for it.

“Every tumor board reaches the same answer.” Boards differ at the margins, especially in mixed pictures. A second multidisciplinary opinion is not an insult to the first.

Questions to ask your care team after the tumor board

The conversation after the board is where the recommendation becomes your plan. Patients who arrive with questions written down tend to leave with clearer answers. These are the ones that experienced nurse specialists say are most worth asking.

• What stage do you think my cancer is, and which test results were most important in reaching that view?
• Was a staging laparoscopy done or recommended, and if not, why not?
• Which biomarker tests were performed on my biopsy, and are any results still pending?
• Why did the board recommend this order of treatment for me specifically, rather than the alternative?
• If chemotherapy comes first, how will you know whether it is working, and what happens if it is not?
• If surgery comes first, will I likely need chemotherapy afterward, and what would that depend on?
• What operation is being proposed, how much stomach would be removed, and how will eating change afterward?
• What are the most common and the most serious side effects of the proposed drug treatment, and who do I call if they happen?
• Was there disagreement at the board, and what were the arguments on each side?
• Are there clinical trials I might be eligible for, and would joining one change the sequence?
• Who is my main point of contact, and how quickly can I reach them?
• Can my case go back to the board if my circumstances or wishes change?

One more question deserves its own line: “What matters most to you about this?” Ask it of yourself before the appointment. A patient who values staying out of hospital, or being well for a particular family event, or avoiding a feeding tube at almost any cost, needs the team to know. The board can weigh those things only if someone brings them into the room, and the person best placed to do that is you.

When to call your doctor: red-flag signs during stomach cancer treatment

Whichever sequence the board recommends, there will be weeks in which you are at home between appointments, and knowing when to pick up the phone is part of the plan. Your team will give you a direct number, often staffed around the clock. Use it without hesitation for any of the following.

During chemotherapy, a temperature at or above the threshold your team specified, or shivering and feeling unwell even without a measured fever, needs same-day contact. Chemotherapy lowers the white blood cells that fight infection, and infection in that state can become serious within hours. Vomiting that prevents you keeping fluids down, diarrhea that is severe or persistent, mouth sores that stop you eating, new chest pain or breathlessness, and sudden swelling or pain in a leg also warrant an urgent call.

Before or after surgery, seek urgent care for vomiting blood or material that looks like coffee grounds, black or tarry stools, inability to swallow or keep down liquids, severe or worsening abdominal pain, a wound that becomes red, hot, swollen or leaks fluid, fever, or breathlessness. A leak at the surgical join can present subtly as feeling generally unwell with a rapid heartbeat, so a vague sense that something is wrong is itself a reason to call.

At any stage, dizziness or fainting, confusion, jaundice, meaning yellowing of the skin or eyes, or rapid unexplained weight loss should be reported promptly.

These signs do not mean the plan has failed. They mean the plan needs the team’s attention now, and the team would rather hear from you ten times unnecessarily than miss the one call that mattered. If you cannot reach your cancer team and symptoms are severe, use emergency services.

Frequently asked questions

Is a tumor board a good thing before stomach cancer surgery?

Yes, mainstream guidance treats multidisciplinary review as the expected standard before major cancer surgery. Observational studies report that board discussion changes the stage or treatment plan in a meaningful minority of cases, usually by catching incomplete staging or adding an option. Whether this lengthens survival is harder to prove, but it reliably ensures a surgeon, an oncologist, a radiologist and a pathologist have all examined your case before anyone operates.

Does every cancer patient have a tumor board?

Not universally, but for a new stomach cancer diagnosis it is now routine in most health systems. The NHS describes stomach cancer treatment as planned by a multidisciplinary team, and most cancer centers in the United States hold gastrointestinal tumor boards. Smaller hospitals often present cases to a regional board by video link. If you are unsure whether your case was discussed, ask your oncologist or nurse specialist directly.

How long do people with stage 4 stomach cancer typically live, and what affects life expectancy?

There is no single honest number, and reputable sources avoid quoting one for an individual. Published averages combine people of very different ages, fitness levels and tumor biology, and newer biomarker-guided drugs have changed the outlook for some subgroups. Factors that matter include where the cancer has spread, HER2 and PD-L1 status, general health and response to the first treatment. Your oncologist can discuss what the evidence suggests for your specific situation.

What foods should people with stomach cancer eat?

The priority is enough protein and energy to hold weight and muscle, not a special anti-cancer diet, because no food has been shown to shrink a stomach tumor. Dietitians usually suggest small, frequent meals, softer textures if swallowing or passage is difficult, and prescribed supplement drinks when ordinary food falls short. After gastrectomy, eating slowly, separating drinks from meals and limiting very sugary foods helps prevent dumping syndrome.

Why would the board recommend chemotherapy before stomach cancer surgery instead of operating right away?

Because for tumors that have grown into the muscle layer or involved lymph nodes, microscopic cancer cells may already have left the stomach, and drug treatment reaches them while surgery cannot. Randomized trials, including the MAGIC trial, showed that chemotherapy before and after surgery improved survival compared with surgery alone in this group. Pre-operative treatment also shows whether the tumor responds to the drugs, which guides later care.

Can I attend my own tumor board meeting?

In nearly all hospitals, no. Boards review many cases in a single hour, each presented in a few minutes, and the format does not accommodate patients. Your voice enters the room through your doctor and nurse specialist, which is why it helps to tell them your priorities, worries and home circumstances before the meeting. Afterward, you are entitled to a full explanation of the recommendation and the reasoning behind it.

What if I disagree with the tumor board's recommendation?

You can decline it, ask for a second opinion, or ask for your case to be re-presented with information the board did not have. A recommendation is advice, not an instruction, and the decision rests with you and your treating team. If you choose a different path, your doctors will explain the trade-offs in neutral terms and continue to support you. Disagreement is a normal part of shared decision-making, not a breakdown in care.

How soon after the tumor board meets does treatment usually start?

It varies with the recommended pathway and with any tests still outstanding. Chemotherapy first requires a consultation, blood tests and often placement of a port; surgery first requires pre-operative fitness checks. Teams aim to move promptly because stomach cancer can affect eating, but the exact timeline is set by your own clinicians. If you feel the wait is too long or your symptoms are changing, tell your nurse specialist so the plan can be reviewed.

Does chemotherapy first mean my stomach cancer is too advanced to operate?

Usually it means the opposite. Chemotherapy before surgery is the recommended sequence for cancers that are locally advanced but still operable, and the team’s intention is to proceed to gastrectomy after the drug course. Cancer that has truly spread too far to operate is managed differently, with systemic treatment as the main approach and surgery reserved for symptom relief. Ask your oncologist plainly which situation applies to you.

What is a multidisciplinary team in stomach cancer care, and is it the same as a tumor board?

Yes, the terms describe the same thing. Multidisciplinary team, or MDT, is the term used in the UK and much of Europe; tumor board is the usual American term. Both refer to a scheduled meeting of surgeons, medical and radiation oncologists, radiologists, pathologists, gastroenterologists and nurse specialists who review each patient’s case together and agree a recommended plan, which is then discussed with the patient.

References

• NHS: Stomach cancer, Treatment
• Cleveland Clinic: Stomach Cancer (Gastric Cancer)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.